(MENAFN- PRLog) VALFIX Medical Ltd. announces the issuance of US Patent No. 10,278,820 titled "Percutaneous valve repair and replacement" issued May 7, 2017. VALFIX Medical is developing trans-catheter solutions for patients suffering from valvular heart disease and heart failure.
"It is exciting to receive this patent as it confirms our technology patentability; our technology is unique and distinct in the market," stated Eli Bar, CEO and Founder of VALFIX Medical. " This patent granted confirms and protects our core technology and adds significant value to our stakeholders"
VALFIX Medical technology is distinguished in its approach to offer both repair and replacement treatment in one procedure. This unique toolbox approach gives more options for interventional cardiologists to deliver the most effective therapy to this complex condition.
Concurrently with the issuance of this patent, VALFIX Medical continues to develop its patent portfolio with other patents in preparation and pending.
About VALFIX Medical:
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.
To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at
Recently, VALFIX Medical also announced the completion of its second round of investment and the recipience of a Research & Development grant from the Israeli Innovation Authority ( https://www.valfixmed.com/blog ).
Media Contact
Devra Igra
+972733744805
MENAFN1305201900703076ID1098516023
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.